Helicobacter pylori diagnostic needs to facilitate risk-stratification 

The Helicobacter pylori infection is the most common bacterial infectious disease in humans: half of the global population is infected. 

The colonization of Helicobacter pylori in the human stomach causes gastritis, gastric ulcers and gastric cancer. Nevertheless, an infection with Helicobacter pylori does not have to cause problems. Depending on the strain, patients can be stratified into low- and high-risk groups. 
The knowledge of the risk-group is important to make an informed choice for treatment and to improve therapy.

ImevaX develops the first rapid test for Helicobacter pylori diagnostic and risk-stratification

  • Although Helicobacter pylori diagnostic exists in many forms – e.g. histology, breath, stool, serology - to this day, none of these tests combines speed, accuracy, ease of use and risk-group stratification at the same time.
  • Along with the vaccine IMX101, we develop a diagnostic test for Helicobacter pylori
  • The Helicobacter pylori rapid test combines unprecedented sensitivity, selectivity and speed while requiring only a small drop of blood. Importantly, the test also has a predictive function: infected patients will immediately know if they are in the low- or high-risk group.